

FY 2020 Significant Financing Events

- **Bellicum Pharmaceuticals** announced on August 21, 2019, the aggregate gross proceeds of \$69.6 million from a \$139.6 million public offering and private placement. The Houston-based company received two CPRIT Product Development awards, including \$5.7 million in 2011 (RP110508) and \$16.9 million in 2016 (DP160057) to support drug development and clinical study for a new T-cell therapy (BPX-501) to solve critical problems associated with non-matched stem cell transplants in children and adults with leukemia.
- **Perimeter Medical Imaging, Inc.** closed an oversubscribed \$4.4 million financing on August 21, 2019, just days after receiving approval for a \$7.4 million CPRIT relocation award (DP190087). The company completed a reverse takeover with New World Resources and started public trading on the TSX Venture Exchange in Toronto on June 24, 2020. The company's stock ticker symbol "PINK" is an allusion to the pink ribbons used during Breast Cancer Awareness Month, driving home the company's dedication to helping surgeons, radiologists and pathologists use Perimeter's imaging technology and AI (Artificial Intelligence) in the fight against breast cancer. Perimeter common shares began trading on the Frankfurt Stock Exchange August 11, 2020, under the trading symbol "4PC," marking a secondary listing for the company. The funds raised by the Houston and Toronto-based company, together with the CPRIT award, support commercializing the company's FDA-cleared OTIS medical imaging technology. The OTIS platform provides clinicians with real-time, ultra-high resolution, sub-surface image volumes of the margin (1-2 mm below the surface) of an excised tissue specimen. Visualizing microscopic tissue structures during clinical procedures may result in better long-term outcomes for patients and lower costs to the healthcare system.
- **Salarius Pharmaceuticals, Inc.**, a clinical-stage oncology company targeting the epigenetic causes of cancers, announced October 28, 2019, that it entered a \$10.9 million common stock purchase agreement, including a \$1.0 million initial common stock purchase, with Aspire Capital Fund, LLC, a Chicago-based institutional investor. The Houston-based company received a Product Development award of up to \$18.7 million in 2016 (DP160014) to support the development and clinical trial of Seclidemstat, Salarius' lead drug candidate, in Ewing sarcoma.
- **Hummingbird Bioscience, Inc.** raised \$25 million in an extended Series B financing round in May 2020. Proceeds will support the discovery of new disease targets, expanding the company's pipeline of first and best-in-class antibody therapeutics, as well as fueling work on co-discovery projects that are part of the multi-target

collaboration agreement signed with Amgen in September 2019. Houston and Singapore-based Hummingbird received a \$13.1 million CPRIT Product Development award in 2019 (DP190027) to develop a monoclonal antibody therapy designed to reverse one of the main causes of resistance to immunotherapy drugs.

- The Nasdaq Capital Market publicly lists Immatics Biotechnologies GmbH and its US subsidiary, **Houston-based Immatics US, Inc.** under the ticker symbol “IMTX” on July 2, 2020. Proceeds from the transaction that included a business combination with Arya Sciences Acquisition Corp. totaled about \$253 million. New investors supporting the transaction include Perceptive Advisors, Redmile Group, Federated Hermes Kaufmann Funds, RTW Investments and Sphera Funds, alongside existing Immatics investors dievini Hopp BioTech, AT Impf and Wellington Partners. Immatics US, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, received a \$19.7 million CPRIT Product Development Award in 2015 (DP150029) to develop a novel personalized T-cell based immunotherapy platform.
- **ESSA Pharma, Inc.** completed a \$36 million public offering and concurrent private placement on August 27, 2019 . Soleus Capital led the offering and included RA Capital Management as a new investor. Existing investors, including BVF Partners LP, Omega Funds and Eventide Funds, among others, also participated in the offering. The company closed a subsequent \$45 million public offering July 31, 2020. New investors included Pfizer Inc., Avidity Partners, CAM Capital, Point72, Ridgeback Capital, Sphera Healthcare and Vivo Capital. Houston and Vancouver-based ESSA received a \$12.0 million CPRIT Product Development award in 2015 (CP130020) to develop novel therapies for the treatment of prostate cancer.
- The Nasdaq Capital Market approved **Medicenna Therapeutics’** common shares for listing on Nasdaq under the symbol MDNA, with trading beginning August 24, 2020. The Houston and Toronto-based company retains its listing on the Toronto Stock Exchange. Medicenna’s lead candidate, MDNA55, has completed a Phase 2b clinical trial for recurrent glioblastoma (rGBM), the most common and uniformly fatal form of brain cancer. Clinicians have studied MDNA55 in five clinical trials involving 132 patients, including 112 adults with rGBM. The FDA has approved Fast-Track and Orphan Drug status for MDNA55. Medicenna received a \$14.1 million CPRIT Product Development award in 2015 (DP150031) to develop MDNA55 to treat glioblastoma and other brain cancers.
- **Molecular Templates, Inc.** announced July 20, 2020, that it raised \$43 million through its At-the-Market facility with participation based on interest received from

Consonance Capital Management. The clinical-stage biopharmaceutical company focuses on discovery and developing its proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs). Austin-based Molecular Templates has received two CPRIT Product Development awards to date, including \$10.6 million in 2011 (CC121020) to develop the targeted ETBs to treat lymphoma, and \$15.2 million in 2016 (DP160071) to develop a novel compound to treat multiple myeloma.